Inhibitor in Medical News
Navigation Links
Inhibitor in Medical News
... the first orally-administered irreversible dual inhibitor of EGFR and HER2,(1) to reach Phase III ... Ingelheim compound, BIBF 1120, an angiogenesis inhibitor that simultaneously inhibits vascular endothelial ... Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer ...
... therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 ... indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to ... a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a ...
... hemophilia A. Additionally, rates of inhibitor formation were reported in both previously ... "It is particularly noteworthy that a low rate of inhibitor formation was observed in this analysis of data pooled from post-marketing surveillance studies. inhibitor formation is a significant challenge for both ...
... II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical ... for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical ... by Elinogrel, a Direct Acting Reversible P2Y12 inhibitor (Presentation #PP-MO-045) Presenter: ...
... our oncology franchise, and the oral multi-kinase inhibitor BAY 73-4506 is one of the promising compounds in ... Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients ... BAY 73-4506 is a novel oral multi-kinase inhibitor with a kinase inhibition profile targeting ...
... in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention ... of CX-4945, the Company's oral protein kinase inhibitor currently in Phase I clinical trials. This ... promise as a potent and selective oral inhibitor of protein kinase CK2, a previously unexploited ...
... serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will ... in the United States. Savella is a dual-reuptake inhibitor that, in-vitro, preferentially blocks the ... a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the ...
... study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. ABT-450 is the ... include ABT-869, a multi-targeted kinase inhibitor and ABT-263, a Bcl-2 family protein antagonist. ... inhibitors as well as our internal polymerase inhibitor program. Abbott has three HCV compounds in ...
... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Dosage of Gleevec ...
... or to letrozole alone. Letrozole, an aromatase inhibitor (AI), is a recognized therapy in the treatment of ... tyrosine kinase inhibitor, and the aromatase inhibitor letrozole versus letrozole monotherapy. At ... Lapatinib is an oral small-molecule inhibitor of the HER2/ErbB2 tyrosine kinase receptor. ...
... and Drug Administration (FDA) for Cinryze(TM) C1 inhibitor (human) as a treatment for acute attacks ... submission this year." About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
... JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to ... contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. ... of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 ...
... "Safety and Efficacy of the Terminal Complement inhibitor Eculizumab in Japanese Patients with ... Uremic Syndrome with the Complement inhibitor Eculizumab," Jens Nuernberger, et al. Abstract: ... "Long-term Efficacy of the Terminal Complement inhibitor Eculizumab in a Patient with Cold Agglutinin ...
... ongoing Phase 1 trials of our orally-active HDAC inhibitor SB939," said Dr. Jan-Anders Karlsson, CEO of ... cancers are consistent with the superior HDAC inhibitor profile that we have previously demonstrated ... Poster No. 136 Discovery of SB939, an HDAC inhibitor with a superior pre-clinical profile SB939 is a ...
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
... million in net sales of Cinryze(TM) (C1 esterase inhibitor [human]), of which $2 million was previously ... commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against ... hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ...... therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 ... indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to ... a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a ...
MO BIO Laboratories, Inc. Launches PowerFood(TM) Microbial DNA Isolation Kit
... Microbial DNA Isolation Kit incorporates patented inhibitor Removal Technology(R) (IRT) to remove ... MO BIO's Power(R) kits contain patented inhibitor Removal Technology(R) for removal of PCR ... procedure. For samples that do not require inhibitor removal, MO BIO's UltraClean(R) line includes ...Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment
... is a novel Cholesterol-Aceyltransferase (ACAT) inhibitor currently in Phase 2 development for the ... An earlier-stage Stearoyl CoA Desaturase 1 (SCD1) inhibitor targeting the same indication was also included ... as was an Activin-Like Kinase 5 (ALK-5) inhibitor currently in preclinical development for reducing ...Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care
... Funding priorities include research into inhibitor development and its treatment; the investigation ... of hemophilia in underserved areas. inhibitor formation is considered by many patient groups as ... system and specific factors have on the risk of inhibitor development. "Through our support of ...Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
... BIIB ) for the selection of a Raf kinase inhibitor development candidate for the treatment of ... being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic," said Daniel Swisher, Sunesis' ... co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration. About ...... hemophilia A. Additionally, rates of inhibitor formation were reported in both previously ... "It is particularly noteworthy that a low rate of inhibitor formation was observed in this analysis of data pooled from post-marketing surveillance studies. inhibitor formation is a significant challenge for both ...
... II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical ... for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical ... by Elinogrel, a Direct Acting Reversible P2Y12 inhibitor (Presentation #PP-MO-045) Presenter: ...
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
... Enzyme Inhibitors II-36 Histone Deacetylase inhibitor II-36 Immunomodulators II-36 Proteasome inhibitor II-36 Tyrosine Kinase Inhibitors II-36 ... Commences Phase I Study for R763 Kinase inhibitor II-41 Swissmedic Approves Celgene's REVLIMID ...New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
... (PIs) - Way Above Others II-5 Protease inhibitor Drugs in Pipeline by Company and Development ... SCH 900518 - Schering's Next-Generation Protease inhibitor II-6 Telaprevir (VX-950) - The Most Promising Pipeline HCV Protease inhibitor II-6 Boceprevir - Schering's PI Class Lead ...New Drug Promising Against Rheumatoid Arthritis
... of patients who had discontinued a previous TNF-a inhibitor treatment because it wasn't effective, ACR 20 was ... suggests that switching patients from one TNF-a inhibitor to golimumab is effective and generally ... whether patients who don't respond to one TNF-a inhibitor might respond to another. More information ...New Cancer Drug Fights Tumors in Those With BRCA Mutations
... Iglehart thinks that combining a PARP inhibitor with chemotherapy drugs that damage DNA might ... with chemo alone to 9.2 months when the PARP inhibitor BSI-201 was added, as well as about a 60 percent ... no additional side effects. The second PARP inhibitor trial involved 54 women with advanced breast ...Potent metastasis inhibitor identified
... Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that ... production of thrombospondin-1, a natural inhibitor of blood vessel growth (angiogenesis), both in ... encouraged him to focus on the metastasis inhibitor -- prosaposin. "You might have a drug right ...Scientists advance safety of nanotechnology
... death. They also showed that using an autophagy inhibitor prevented the cell death and counteracted ... found that treating the cells with an autophagy inhibitor known as 3MA significantly inhibited the ... mice, but injecting the mice with the autophagy inhibitor 3MA before introducing the nanoparticles ...Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
... Mechanistic and Therapeutic Potential of sEH inhibitor in Treating Type 2 Diabetes - SOUTH SAN ... soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical program for the ... -- "AR9281, a Soluble Epoxide Hydrolase inhibitor - Efficacy in a DIO Mouse Model plus ...... our oncology franchise, and the oral multi-kinase inhibitor BAY 73-4506 is one of the promising compounds in ... Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients ... BAY 73-4506 is a novel oral multi-kinase inhibitor with a kinase inhibition profile targeting ...
... in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention ... of CX-4945, the Company's oral protein kinase inhibitor currently in Phase I clinical trials. This ... promise as a potent and selective oral inhibitor of protein kinase CK2, a previously unexploited ...
... serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will ... in the United States. Savella is a dual-reuptake inhibitor that, in-vitro, preferentially blocks the ... a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the ...
Science Makes Inroads Against Prostate, Other Cancers
... Angeles. Her team targeted brain cancer with an inhibitor called "dimethyl-celecoxib". Celecoxib may ... It's the more scientific name for the cox-2 inhibitor drug, Celebrex, which has been used as a pain ... of two new agents: a histone deacetylase inhibitor called LBH589 and a ...... study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. ABT-450 is the ... include ABT-869, a multi-targeted kinase inhibitor and ABT-263, a Bcl-2 family protein antagonist. ... inhibitors as well as our internal polymerase inhibitor program. Abbott has three HCV compounds in ...
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
... "As the proud stewards of the only approved C1 inhibitor therapy on the market, ViroPharma is committed to ... through March 24, 2009. About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack
... the blood thinner Plavix, plus a proton pump inhibitor such as Prilosec or Nexium, may be at increased ... the PPI and Plavix," he said. A proton pump inhibitor should only be prescribed to patients who have ... that people taking Plavix and a proton pump inhibitor after a heart attack had a dramatically higher ...SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results
... to initiate clinical trials with SGI-1776, an inhibitor of PIM kinases. "SuperGen ... MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting Rad51 is not toxic to human primary ... FDA to initiate clinical trials with SGI-1776, an inhibitor of PIM kinases. The clearance of the IND ...... is recommended (400 mg once daily). If the strong inhibitor is discontinued, a washout period should be ... to the indicated dose. Tasigna is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. ... is metabolized by the CYP3A4 isoenzyme and is an inhibitor of CYP3A4, CYP2D6, and CYP2C9. Dosage of Gleevec ...
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
... an investigational oral non-nucleoside polymerase inhibitor that Anadys is developing for the treatment of ... reported for any other non-nucleoside polymerase inhibitor in a monotherapy study. A number of clinical, ... agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous ...Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
... found no such association with the proton pump inhibitor pantoprazole or with other acid-lowering ... College of Cardiology recommend proton pump inhibitor therapy for many patients following a heart ... of patients worldwide will take a proton pump inhibitor with clopidogrel. "Depending on the ...Arterial infusion using gabexate mesilate: Is it effective therapy for severe acute pancreatitis?
... regional arterial infusion (CRAI) with protease inhibitor of nafamostat mesilate and antibiotics has proven ... systemic inflammation. The level of protease inhibitor in pancreatic tissues after CRAI using nafamostat ... by CRAI. On the other hand, the level of protease inhibitor in pancreatic tissues after CRAI using gabexate ...Osteoporosis Drug Seems to Shrink Breast Tumors
... breast cancer who took the aromatase inhibitor exemestane (Aromasin) had a 15 percent relative ... another HER2 inhibitor, with an aromatase inhibitor (in this case, letrozole) prolonged ... took tamoxifen but then switched to an aromatase inhibitor after initial treatment. "The data are still ...... or to letrozole alone. Letrozole, an aromatase inhibitor (AI), is a recognized therapy in the treatment of ... tyrosine kinase inhibitor, and the aromatase inhibitor letrozole versus letrozole monotherapy. At ... Lapatinib is an oral small-molecule inhibitor of the HER2/ErbB2 tyrosine kinase receptor. ...
Estrogen pills can benefit women with metastatic breast cancer
... "We thought acquired resistance to aromatase inhibitor therapy was permanent," Ellis says. "But now ... The study measured how many women with aromatase inhibitor therapy-resistant metastatic breast cancer ... on estrogen, they could go back to an aromatase inhibitor that they were previously resistant to and see a ...... and Drug Administration (FDA) for Cinryze(TM) C1 inhibitor (human) as a treatment for acute attacks ... submission this year." About Cinryze C1 inhibitor (human) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 inhibitor product that has been approved by FDA for routine ...
Combining targeted therapy drugs may treat previously resistant tumors
... of those animals with an investigational PI3K inhibitor did lead to rapid tumor regression. Since ... the investigators also tested the PI3K inhibitor in mice with K-Ras-stimulated tumors. That ... treated the animals with an investigational MEK inhibitor and with a combination of both drugs. Treatment ...... JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to ... contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. ... of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 ...
Research demonstrates differing genetic makeup of lung cancer in African-American patients
... when taking erlotinib and gefitinib common EGFR inhibitor drugs. Previous studies have determined that ... likelihood of major clinical responses to EGFR inhibitor drugs while a higher copy number of EGFR is a ... of mutation, predicts a better outcome with EGFR inhibitor drugs. "The findings of this study were ...... "Safety and Efficacy of the Terminal Complement inhibitor Eculizumab in Japanese Patients with ... Uremic Syndrome with the Complement inhibitor Eculizumab," Jens Nuernberger, et al. Abstract: ... "Long-term Efficacy of the Terminal Complement inhibitor Eculizumab in a Patient with Cold Agglutinin ...
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
... plans and launch of Cinryze C1 inhibitor (human), which has been recently approved by the ... strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis ... hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ...... ongoing Phase 1 trials of our orally-active HDAC inhibitor SB939," said Dr. Jan-Anders Karlsson, CEO of ... cancers are consistent with the superior HDAC inhibitor profile that we have previously demonstrated ... Poster No. 136 Discovery of SB939, an HDAC inhibitor with a superior pre-clinical profile SB939 is a ...
Penn researchers use honeybee venom toxin to develop a new tool for studying hypertension
... and thus have low blood pressure," notes Lu. "An inhibitor specifically against these kidney channels will ... idea to be tested." Developing a specific inhibitor for one type of Kir channel has been challenging ... of TPNLQ demonstrates that a highly specific inhibitor of potassium channels can be engineered. TPNLQ ...LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
... bone fractures among patients using proton pump inhibitor (PPI) drugs. The drugs are used to treat and ... [proton pump inhibitor __title__ Proton Pump inhibitor Risks] (PPI) drugs of the potential for serious ...Other ContentsimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmuneimmuneinfertilityinfertilityinfertilityimmunologyimmunologyimmunologyimmunologyimmunologyimmunologyimmunologyimmunologyfilamentfilamentfilamentintermediateintermediateintermediateintermediateintermediateintermediateintermediateintermediateintermediateinsulininsulininsulininsulininsulininsulininsulininsulinOther TagsAllograftCagesteerableTPS
(Date:11/25/2009)...NA, Calif.Scientists at the California Institute o...a primitive emotion-like behavior in the fruit fly...hich may be relevant to the relationship between t... hyperactivity disorder (ADHD), are described in t... Drosophila brain contains only about 20,000 neu...
(Date:11/25/2009)...tember 11, firefighters, police officers and ambul...he World Trade Center complex. They battled to sav... for survivors, tackled fires and evacuated as man...an estimated 17,000 people. And making their jobs ...: frightened workers and their relatives jammed mo...
(Date:11/25/2009)...he course of a lifetime, the heart pumps some 250 ...rder to do this, the muscle fibers of the heart ha...ded by Dr. Wolfgang Rottbauer, vice chair of the D... Hospital (Chairman: Prof. Dr. H. A. Katus), has d...ability of the smallest muscular unit, the sarcome...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Magic box for mission impossible 2Magic box for mission impossible 3New genetic cause of cardiac failure discovered 2Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer 3B Strengthens Its Commitment to the Nursing Market 60802 1Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer 3B Strengthens Its Commitment to the Nursing Market 60802 2Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer 3B Strengthens Its Commitment to the Nursing Market 60802 3AVMA Updates H1N1 Flu Resources for Pet Owners Veterinarians 60797 1Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 1Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 2Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 3Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 4Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 5Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 6(Date:11/27/2009)...may reduce future disease burden, researchers say ...Encouraging city dwellers to walk and bicycle inst...health benefits than increased used of low-emissio...study compared the projected health effects in 203...r London, England, and Delhi, India: business-as-...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...te (TM) has been shown in studies to be effective ...ed by an overload of copper, and certain metastati...r, is known about how the drug works at the molecu...versity researchers now has provided an invaluable... to copper-loaded metallochaperones. The drug sequ...
(Date:11/26/2009)...tal (RTDental), a leading dental group practice in...sion of its services to include LUMINEERS by a cer... Durham, NC (PRWEB) -- Res...Dr. Doug Macmillan, an experienced LUMINEERS Den...aining seminar. RTDental’s ability to fulfi...
(Date:11/25/2009)...wswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. ...will host two investor events in December: ,, ....m. CT/10:00 a.m. ET ,, Principal investigato...filzomib in relapsed and/or refractory multiple my... Hematology (ASH) Annual Meeting and Exposition in...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2[0] More Foot Power, Less Car Pollution Best for Health[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[1] Research sheds light on workings of anti-cancer drug[0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental [0] Onyx Pharmaceuticals Announces December 2009 Investor Events
AllograftCageIntervertebralNeuroendoscopeProximitysteerableGingivoplastyHSMMotordrillZMMEmaxRadiotranslucentRetractionTPS
Other Tagsoncology 2oncology 3clusters 2clusters 3clusters 4partnership 2partnership 3partnership 4details 2details 3details 4details 5details 6details 7details 8details 9dynamics 2dynamics 3dynamics 4dynamics 5
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |